Segall Bryant & Hamill LLC Has $2.66 Million Stock Position in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Segall Bryant & Hamill LLC lowered its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 23.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 20,470 shares of the medical instruments supplier’s stock after selling 6,402 shares during the period. Segall Bryant & Hamill LLC’s holdings in Mesa Laboratories were worth $2,658,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Mesa Laboratories by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 373,397 shares of the medical instruments supplier’s stock valued at $40,973,000 after acquiring an additional 3,119 shares in the last quarter. Geneva Capital Management LLC raised its stake in shares of Mesa Laboratories by 2.0% in the 3rd quarter. Geneva Capital Management LLC now owns 191,976 shares of the medical instruments supplier’s stock valued at $24,930,000 after purchasing an additional 3,732 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Mesa Laboratories by 7.1% in the second quarter. Dimensional Fund Advisors LP now owns 131,891 shares of the medical instruments supplier’s stock valued at $11,444,000 after purchasing an additional 8,722 shares in the last quarter. Raymond James & Associates boosted its position in shares of Mesa Laboratories by 8.4% during the second quarter. Raymond James & Associates now owns 80,739 shares of the medical instruments supplier’s stock worth $7,006,000 after buying an additional 6,283 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of Mesa Laboratories by 21.8% during the third quarter. Principal Financial Group Inc. now owns 35,107 shares of the medical instruments supplier’s stock worth $4,559,000 after buying an additional 6,292 shares in the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

Mesa Laboratories Trading Up 8.2 %

NASDAQ MLAB opened at $109.09 on Friday. Mesa Laboratories, Inc. has a 12 month low of $83.68 and a 12 month high of $141.17. The company has a current ratio of 0.70, a quick ratio of 0.51 and a debt-to-equity ratio of 0.65. The stock has a 50 day moving average of $121.64 and a 200-day moving average of $114.56. The company has a market cap of $592.47 million, a PE ratio of -2.31 and a beta of 0.87.

Mesa Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 29th will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, November 29th. This represents a $0.64 annualized dividend and a dividend yield of 0.59%. Mesa Laboratories’s dividend payout ratio is presently -1.40%.

Analyst Ratings Changes

A number of equities analysts have weighed in on MLAB shares. Wells Fargo & Company started coverage on Mesa Laboratories in a research report on Tuesday, August 27th. They set an “underweight” rating and a $120.00 price target for the company. StockNews.com lowered shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, November 13th. Finally, Evercore ISI increased their price objective on shares of Mesa Laboratories from $120.00 to $160.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st.

Insider Transactions at Mesa Laboratories

In other news, CEO Gary M. Owens sold 2,518 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $113.62, for a total value of $286,095.16. Following the transaction, the chief executive officer now owns 45,888 shares of the company’s stock, valued at approximately $5,213,794.56. This represents a 5.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Brian David Archbold sold 1,499 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $125.00, for a total value of $187,375.00. The disclosure for this sale can be found here. 4.40% of the stock is owned by company insiders.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.